© 2020 MJH Life Sciences and OncLive. All rights reserved.
© 2020 MJH Life Sciences™ and OncLive. All rights reserved.
September 22nd 2020
A biologics license application has been submitted to the FDA for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.
Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.
Ivosidenib demonstrated a consistent trend toward improved overall survival compared with placebo in treatment-naïve patients with IDH1-positive cholangiocarcinoma, although the benefit was not determined to be statistically significant.
Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory
diffuse large B-cell lymphoma.
Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.